Drug Profile
Deuterium-modified praziquantel - Concert Pharmaceuticals
Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Concert Pharmaceuticals
- Class 3-ring heterocyclic compounds; Cyclohexanes; Isoquinolines; Organic deuterium compounds; Pyrazines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schistosomiasis
Most Recent Events
- 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schistosomiasis in USA (PO)
- 15 Nov 2011 Preclinical trials in Schistosomiasis in USA (PO)